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Clostridium difficile infection (CDI) are the leading cause of world-wide nosocomial
acquired diarrhea. The current main clinical challenge in CDI is the elevated rate of
infection recurrence that may reach up to 30% of the patients, which has been associated
to the formation of dormant spores during the infection. We sought to characterize
the effects of oral administration of specific anti-spore IgY in mouse models of CDI
and recurrent CDI. The specificity of anti-spore IgY was evaluated in vitro. In both,
initiation mouse model and recurrence mouse model, we evaluated the prophylactic
and therapeutic effect of anti-spore IgY, respectively. Our results demonstrate that
anti-spore IgY exhibited high specificity and titers against C. difficile spores and reduced
spore adherence to intestinal cells in vitro. Administration of anti-spore IgY to C57BL/6
mice prior and during CDI delayed the appearance of the diarrhea by 1.5 day, and
spore adherence to the colonic mucosa by 90%. Notably, in the recurrence model,
co-administration of anti-spore IgY coupled with vancomycin delayed the appearance
of recurrent diarrhea by a median of 2 days. Collectively, these observations suggest
that anti-spore IgY antibodies may be used as a novel prophylactic treatment for CDI, or
in combination with antibiotics to treat CDI and prevent recurrence of the infection.
Keywords: Clostridium difficile spores, chicken immunoglobulin IgY, immunotherapy, passive immunization,
recurrent CDI, exosporium, germination, sporulation
INTRODUCTION
Clostridium difficile is a spore-forming Gram-positive anaerobic bacterium and is the most
frequently identified cause of nosocomial diarrhea. It has been associated with epidemics of
diarrhea in hospitals and long-term care facilities (Cohen et al., 2010; Evans and Safdar, 2015).
Symptoms associated with C. difficile infections (CDI) range from asymptomatic colonization
to severe diarrhea, pseudomembranous colitis, toxic megacolon, colonic perforation and even
death (Gerding et al., 1995). A narrow set of antibiotics (i.e., metronidazole and vancomycin) are
currently being used to treat CDI (Evans and Safdar, 2015); albeit these antibiotics resolve the first
episode of the disease, the rate of infection recurrence can be as high as 30% (Bakken et al., 2013).
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Unlike most enteropathogens, during the infection C. difficile
initiates a sporulation cycle that culminates with the production
of metabolically dormant spores are shedded to the environment
causing disease persistence and transmission (Deakin et al.,
2012); these spores survive inside cause recurrence of the
infection. Given the natural resistance of C. difficile spores to
antibiotics, they remain in dormant state and may germinate
upon cease of antibiotic treatment, generating a new infection
(Rupnik et al., 2009). New spore-aimed therapies targeting
the removal of C. difficile spores from a susceptible host and
during CDI may prevent the initiation and recurrence of
the disease, respectively. Consequently, the opsonization of C.
difficile spores with spore-specific antibodies may be conceived
as a possible strategy to reduce C. difficile spore-host interactions
and C. difficile spore-load in the host.
Chicken IgY has several advantages over other
immunoglobulins for the development of passive
immunotherapy: (i) current regulations of the Federal Drug
Administration (FDA) classifies the oral consumption of IgY
as “Generally Recognized as Safe” (GRAS), facilitating the
regulations for human consumption of pathogen-specific IgY
(Rahman et al., 2013); (ii) oral administration of IgY does not
trigger an adaptive immune response against administered
immunoglobulin (Nilsson et al., 2007); (iii) the structure of IgY is
not recognized by intestinal epithelial Fc-receptors in mammals
and does not activate mammalian complement (Carlander et al.,
2000; Kovacs-Nolan and Mine, 2012); (iv) IgY exhibits high
antigen-specificity and avidity (Kovacs-Nolan and Mine, 2012),
and faster reaction times with the antigen than mammalian IgG
(Rahman et al., 2013); and (v) IgY retains their activity during
transit through the gastrointestinal tract (Kovacs-Nolan and
Mine, 2012). Notably, attempts to use passive immunization to
treat CDI have focused on both toxins, TcdA and TcdB, and on
structural components of vegetative cells (Mulvey et al., 2011;
Zhang S. et al., 2015). However, anti-spore IgY have not been
explored.
Consequently, the aim of this work was to raise and
characterize anti-spore IgY and to evaluate if its oral
administration could protect mice from the initiation and
recurrence of the infection. In this work, we demonstrate the
feasibility of C. difficile spore-targeted therapies to prevent the
initiation and recurrence of CDI.
MATERIALS AND METHODS
Clostridium Difficile Strains
C. difficile strain R20291 (RT027) is an epidemic strain that
caused outbreaks and has been described elsewhere (McEllistrem
et al., 2005; He et al., 2010). C. difficile clinical isolates
PUC31 (RT046), PUC38 (RT082) and PUC104 (RT097) were
obtained from Chilean patients and have been described
elsewhere (Plaza-Garrido et al., 2015). C. difficile strains
were grown in a Bactron II-2 anaerobic chamber (Shellab,
OR, U.S.A.) in 3.7% of Brain Heart Infusion supplemented
with 0.5% yeast extract (BHIS) broth or on BHIS agar
plates.
Spore Purification
C. difficile spores were purified as described elsewhere (Mora-
Uribe et al., 2016). Spore suspensions were prepared by plating
a 1:500 dilution from an overnight culture onto 3% Trypticase
Soy-0.5% yeast extract (TY) agar plates and incubated for 5 days
at 37◦C under anaerobic conditions. Spores were harvested with
ice-cold sterile distilled water and purified with 50% Nicodenz
as previously described (Sorg and Sonenshein, 2008). Spore
suspensions were purified until they were>99% free of vegetative
cells, sporulating cells and cell debris as determined by phase
contrast microscopy and the concentration was quantified with
a Neubauer Chamber (Sigma-Aldrich, U.S.A.) prior to use.
Chicken Immunization Protocol
Chicken immunoglobulins (IgY) specific for C. difficile spores
from the epidemic strain R20291 were produced as described
by the manufacturer (AvesLabs, OR, U.S.A.). Briefly, 5 × 109
R20291 spores were fixed in 4% paraformaldehyde for 16 h at
4◦C, rinsed with PBS, and aliquots of 500 µL PBS containing
2.5 × 108 spores were stored at −20◦C until use. Two hens were
immunized intramuscularly at four separate locations of the hen’s
breast tissue (250 µL per site) with a 1 ml solution containing
500 µL antigen mixed 1:1 with Freund’s complete adjuvant. After
weeks 3, 5, and 7, booster shoots of 500 µL antigen mixed 1:1
with incomplete Freund’s (50%) adjuvant were administered.
Eggs were collected from weeks 7 to 11 and were used for IgY
purification of each different hen.
Purification of Anti-C. difficile Spore IgY
Two independent batches of chicken immunoglobulins were
obtained as pure IgY from AvesLab as described by manufacturer
using described protocols (Akita and Nakai, 1992, 1993; Liou
et al., 2010). However, since the IgY suspension had a IgY(∆Fc)
isotype which lacks the Fc region (Lundqvist et al., 2006), a
further purification step was applied to obtain purified full
length IgY fraction by salting out precipitation under acidic
conditions, as described (Hodek et al., 2013). Briefly, AvesLab
IgY suspension was diluted in 20 volumes of 8.8% NaCl w/v,
adjusted at pH 4.0 with HCl and incubated with shaking for
2 h at room temperature. The precipitated IgY was collected
by centrifugation (3,700 g for 20 min) at 4◦C and the pellet
resuspended in 1 volume of PBS, filtered sterilized, and stored
at −20◦C until use. The purity of purified IgY was analyzed by
SDS-PAGE andWestern blot analysis using anti-IgY donkey IgG
conjugated with HRP (Abcam, U.S.A.).
Enzyme-Linked Immunosorbent Assay of
Antibody Titer against C. difficile Spores of
the Epidemic Strain R20291
Antibody titers were assessed by enzyme-linked immunosorbent
assay (ELISA) using previously described protocols (Snyder et al.,
1983). Briefly, 96-well ELISA plates (Grainer, Germany) were
incubated for 16 h at 4◦C with 100 µL of PBS containing 1.6
× 107 spores of strain R20291. Unbound spores were removed
by washing the well three times with 150 µL of PBS. Bounded
spores were further blocked with 2% BSA in PBS-0.05% Tween
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20 (PBS-T) for 1 h at 37◦C, rinsed 5 times with 150 µl PBS-
T. Wells were next incubated with serial dilutions of anti-spore
IgY in 1% BSA in PBS-T for 2 h at 37◦C, rinsed five times
with 150 µL of PBS-T, and further incubated with a 1:10,000
dilution of anti-chicken IgY-horseradish peroxidase conjugate
(Anti-IgY HRP) (Abcam, U.S.A.) in 1% BSA in PBS-T for 1
h at 37◦C. Wells were finally rinsed five times with 150 µL
of PBS-T. Colorimetric reaction was initiated upon addition of
50 µL of reaction buffer (0.05 M citric acid, 0.1 M disodium
hydrogen phosphate) containing 2mg/mL of o-phenlyendiamine
(Sigma-Aldrich, U.S.A.) and 0.015% of H2O2 (Merck, Germany).
Reaction was stopped after 20 min with 25 µL of 4.5 N of
H2SO4 and absorbance was measured at 492 nm. Background
reactivity was performed using IgY from eggs obtained prior
immunization. All experiments were repeated three times in
triplicate. Antibody titers were analyzed as previously described
(Snyder et al., 1983).
Immunofluorescence
Spores were fixed on poly-L-lysine-coated glass cover slides with
3% paraformaldehyde (pH 7.4) for 20 min. Next, fixed spores
were rinsed three times with PBS, blocked with 1% bovine
serum albumin (BSA) for 1 h and further incubated for 1 h at
room temperature with 1:100 of anti-spore IgY. Covers were
rinsed three times with PBS and incubated for 1 h at room
temperature with 1:500 goat anti-IgY conjugated with Alexa
488 (Invitrogen) in PBS with 1% BSA and washed three times
with PBS and once with sterile distilled water. Samples were
then dried at room temperature for 30 min, and covers were
mounted using Dako Fluorescence Mounting medium (Dako,
North America) and sealed with nail polish. Samples were
analyzed in an Olympus BX53 fluorescence microscope. Control
experiments included spores without primary antibodies, which
did not yield fluorescence signal (data not shown). Using ImageJ
(v1.48, NIH), an outline was drawn around 300 spores for
experimental condition (n = 100 per replicate) including the
integrated density and the mean fluorescence, along with several
adjacent background readings.
SDS-PAGE and Western Immunoblotting of
C. difficile Vegetative Cells, Spores and
Murine Fecal Bacterial Cells
Samples (10 µL) containing 4 × 107 cells or spores of C. difficile
strain R20291, or similar number of cells of murine microbiota
bacterial cells in SDS-PAGE loading buffer, were electrophoresed
on SDS-PAGE gels (12% acrylamide). Proteins were transferred
to a nitrocellulose membrane (Bio-Rad) and blocked for 1 h
at room temperature with 2% BSA-Tris buffered saline pH 7.4
(TBS). These Western blots were probed with a 1:5,000 dilution
of anti-spore IgY in 2% BSA-TBS-0.1% Tween 20 (2% BSA-
TTBS) for 2 h at room temperature, rinsed three times with
TTBS and incubated a 1:10,000 rabbit anti-IgY HRP in TTBS
for 1 h at room temperature. Membranes were rinsed three times
with TTBS and a final wash with TBS. HRP activity was detected
with a chemiluminescence detection system (Fotodyne Imaging)
by using PixoMax sensitive chemiluminescent detection system
HRP-substrate (RockLand Immunochemicals).
ELISA of Anti-Spore IgY against C. difficile
Vegetative Cells and Murine Fecal
Microbiota
Murine fecal microbiota was obtained from untreated and
antibiotic treated mice. Feces (250 mg) were hydrated in 10
ml PBS at 4◦C for 16 h with gentle stirring. Fecal macroscopic
organic material was removed by low speed centrifugation (500
rpm; 27 × g) at 4◦C for 5 min, this step was repeated four
times and cells were resuspended to a final concentration of
1.6 × 108 cell/mL. To evaluate the immunoreactivity of IgYs
with conformational antigens, 96-well ELISA plates (Grainer,
Germany) were incubated for 16 h at 4◦C with 100 µL of PBS
containing 4 × 107 fecal microbiota bacterial cells, spores or
vegetative cells ofC. difficile. Unbound cells/spores were removed
by washing the well three times with 150 µL of PBS and antibody
titers were analyzed as previously described (Snyder et al., 1983).
Germination Assay
C. difficile spores were pre-incubated for 2 h at 37◦C with various
concentrations of anti-spore IgY, and unbound IgY was removed
by three washes. IgY-treated and untreated spores were serially
diluted and plated onto BHIS-ST agar plates and incubated
anaerobically at 37◦C for 36 h.
Adherence Assay
Caco-2 cells were seeded (5 × 105 cells per well) onto 96-
well plates and incubated until cells became confluent,
and further incubated for 8 days, obtaining differentiated
Caco-2 monolayers. Differentiation was assessed by
immunofluorescence using sucrose-isomaltase as a marker
for the appearance of microvilli (Mora-Uribe et al., 2016). Before
infection, C. difficile spores were pre-incubated for 2 h at 37◦C
with various concentrations of anti-spore IgY, and unbound IgY
was removed by three washes with PBS. Pre-incubated spores
were used to infect monolayers of differentiated Caco-2 cells at
a multiplicity of infection (MOI) of 10 for 3 h at 37◦C and 5%
CO2 atmosphere. Unbound spores were removed by 3 washes
with PBS. Caco-2 cells were then lysed with 95 µl 0.06% Triton
X-100 for 30 min at 37◦C, and appropriate dilutions, containing
adhered spores, were plated onto BHIS-ST agar plates and
incubated under anaerobic conditions at 37◦C for 36 h. For total
C. difficile spore counts, infected Caco-2 cells were directly lysed
and plated onto BHIS-ST agar and incubated anaerobically at
37◦C for 36 h. Numbers of colony forming units (CFU) were
determined and percentages of adherence were calculated using
the following formula: ([final CFU/mL]/[initial CFU/mL]) ×
100; where initial CFU correspond to colonies from unwashed
wells. These experimental conditions do not trigger germination
of C. difficile spores (Paredes-Sabja and Sarker, 2011).
Mice
Pathogen-free C57BL/6mice (age 6–9 weeks) were obtained from
the Institute of Public Health of Chile (Santiago, Chile). All mice
used in the experiments were housed in groups of 4% under
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conventional conditions at the Animal Infection Facility of the
Microbiota-Host Interactions and Clostridia Research Group of
Universidad Andrés Bello (Santiago, Chile), for 2 weeks before
the initiation of the study. Food (Chow; Prolab RMH 3000
rodent diet, St. Louis, MO, U.S.A), water, bedding and cages were
sterilized prior use. All experimental protocols were conducted
in strict accordance with, and under the formal approval of
the Institutional Animal Ethics Committee of the Universidad
Andrés Bello.
Animal Infection Model
Prior to infection, mice were pre-treated with antibiotic cocktail
of kanamycin (4.2 mg/kg body weight; Sigma-Aldrich, U.S.A.),
gentamicin (3.5 mg/kg body weight; Sigma-Aldrich), colistin (4.2
mg/kg body weight; Sigma-Aldrich), metronidazole (21.5 mg/kg
body weight; Sigma-Aldrich) and vancomycin (4.5 mg/kg body
weight; Sigma-Aldrich) for 3 days, in the drinking water (Chen
et al., 2008). After the treatment, mice received sterile water for
2 days, followed by intraperitoneal administration of a single
dose of clindamycin (10 mg/kg) 1 day before C. difficile challenge
(Chen et al., 2008). All animals were infected orogastrically with
200 µl PBS containing 6 × 107 spores of strain R20291. Mice
were housed individually in sterile cages with ad libitum access
to food and water. All procedures and mouse handling were
performed aseptically in a biosafety cabinet to contain spore-
mediated transmission.
Preliminary evaluation of dose efficacy includes anti-spore IgY
administration prior to infection of mice (n = 4 per treatment),
consisting in orogastric administration of a first dose of 50 µl of
PBS containing 100 and 200 µg of anti-spore IgY or 200 µg of
pre-immunized IgY 2 h prior to infection by oral gavage, a second
dose 6 h post-infection and thereafter doses every 24 h during the
following 3 days.
To evaluate the effect of orogastric administration of a higher
dose of anti-spore IgY prior to infection of mice (n = 12 per
treatment), a first dose of 50 µl of PBS containing 600 µg anti-
spore IgY or PBS was given by oral gavage 2 h prior to infection.
A second dose was given 6 h post-infection, and thereafter doses
where given every 24 h during the following 3 days.
To evaluate the effect of anti-spore IgY in the prevention of
recurrence of CDI, two groups of mice (n= 10) were pre-treated
with antibiotics and infected with C. difficile as described above.
From days 3 to 9, mice were orally administered with 50 µl
of PBS containing vancomycin (50 mg/kg; Sigma-Aldrich) or a
combination of vancomycin (50 mg/kg) and anti-spore IgY (600
µg/dose).
The clinical condition of mice was monitored daily with a
scoring system. The presence of diarrhea was classified according
to severity as follows: (i) normal stool (score = 1); (ii) color
change/consistency (score = 2); (iii) presence of wet tail or
mucosa (score= 3); (iv) liquid stools (score= 4). A score higher
than 1 was considered as diarrhea (Warren et al., 2013). Other
clinical symptoms analyzed were weight, physical aspect (i.e.,
abnormal/hunched gait, piloerection), spontaneous behavior
(i.e., lethargy, inactivity or lack of mobility) and emaciation were
monitored as described (Deakin et al., 2012). Moribund mice or
mice displaying overt signs of disease should sacrificed.
Quantification of Spores from Feces and
Colon
Fecal samples were collected daily and 40mg of feces were
hydrated with 500 µl in sterile MilliQ water for 16 h at
4◦C, and then added 500 µL of absolute ethanol (Sigma-
Aldrich) which were incubated for 60 min at room temperature.
Samples were serially diluted and plated onto selective medium
supplemented with taurocholate (0.1% w/v), Cefoxitin (16
µg/mL), L-cycloserine (250 µg/mL) (TCCFA plates). The plates
were incubated anaerobically at 37◦C for 48 h, colonies counted
and results expressed as the Log10 [CFU/gram of feces].
Colonic tissue was collected from mice, washed three times
with PBS with a syringe. The spore load in the colon was
determined using the first centimeter (cm) of the proximal
region of the colon measured from the base of the cecum;
∼70mg of tissue was obtained, hydrated with 700 µL of PBS and
homogenized. The amounts of spores were quantified by heat
treating the sample at 65◦C to kill vegetative cells and plating
onto TCCFA plates. The plates were incubated anaerobically at
37◦C for 48 h. Finally, the colony count was expressed as the
Log10 [CFU/gram of colon].
IgG Reactivity Assay
Blood from of infected mice were collected by cardiac puncture.
After 30 min at 37◦C, sample was centrifuged at 4,000 rpm for 20
min at 4◦C and the supernatant, containing the serum fraction
was stored at −20 until use. To assess the reactivity of serum
IgG against C. difficile spores and IgY from treatment, ELISA
assay was performed in wells incubated with R20291 spores (1.6
× 107 spores) or IgY (100 µg/mL), respectively. After blocking
and 3 washes with 100 µL PBS, mouse serum was added at 1/500,
1/1,000, and 1/2,000 dilution and incubated for 2 h at 37◦C.
After that, non-adherent IgG was removed from the wells with
5 washes with PBS-T, followed by incubation with secondary
antibody, anti-mouse HRP, for 1 h at 37◦C. Finally, colorimetric
reaction was developed as described before.
Cecum Content Cytotoxicity Assay
Vero cell cytotoxicity was performed as described previously
(Theriot et al., 2011). Briefly, Vero cells were seeded in a 96-
well flat bottom microtiter plate at a density of 105 cells/well.
Cecum contents from mice were suspended in PBS at a ratio
of 1:10 (10 µl of PBS per mg of cecum content), vortexed and
centrifuged (14,000 rpm, 5 min). Supernatant was filter sterilized
and serially diluted in DMEM supplemented with 10% FBS and
1% penicillium streptomycin and 100 µl of each dilution was
added to Vero cell wells. After 16 h of incubation at 37◦C, plates
were screened for cell rounding. The cytotoxic titer was defined
as the reciprocal of the highest dilution that produced rounding
in at least 80% of Vero cells per gram of luminal samples under
X200 magnification.
Histopathology Evaluation
Light microscopy evaluation was performed by a veterinary
pathologist in a blinded manner (unaware of the time points
and experimental design at the time of evaluation). Histological
lesions were categorically scored from 0 (normal) to 4 (most
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severe) for edema, inflammation, and epithelial damage using a
scoring system reported previously (Kelly et al., 1994). Individual
parameter scores were added for a summary of the histological
score with a maximum value of 12. Samples from uninfected
mice included as internal negative controls received a score of
zero using the same grading scale and assessed by the same
pathologist. Representative photomicrographs were taken using
a MicroPublisher 3.3 megapixels digital camera mounted to an
Olympus BX53 light microscope.
Statistical Analysis
Prism 6 (GraphPad Software, Inc.) was used for statistical
analysis. Significance between groups was done by Mann-
Whitney unpaired t-test. Comparative analysis between groups
for in vitro experiments was analyzed by analysis of variance with
post-hoc Student t-tests with Bonferroni corrections for multiple
comparison, as appropriate. A P-value of ≤0.05 was accepted as
the level of statistical significance. Differences in the percentages
of mice with normal stools, as well as percentages of mice with
C. difficile infection were determined with by Gehan-Breslow-
Wilcoxon test.
RESULTS
Purification of Full Length Chicken
Anti-Spore IgY
Previous studies of passive immunotherapies against C. difficile
infections have aimed to neutralize toxins A and B (Zhang Z.
et al., 2015), flagella or surface layer proteins (Mulvey et al.,
2011). In the present study, we aim to evaluate whether oral
administration of anti-spore IgY could prevent the initiation
of the infection in a mouse model when administered alone,
or the recurrence of the infection when co-administered with
vancomycin. Given the emergence of C. difficile NAP1/BI/027
strains, including strain R20291, which has caused epidemics of
CDI (O’Connor et al., 2009; He et al., 2013), we selected this strain
to immunize hens. In addition, this strain is a good sporulating
strain in vitro, and the mouse models of initiation and recurrence
for this strain have been well characterized (Deakin et al., 2012;
Winston et al., 2016).
SDS-PAGE analysis of IgY suspensions of both batches of anti-
spore IgY (7245 and 7246) obtained from AvesLab, revealed the
presence of the three dominant bands, a 67-70-kDa molecular
size species that represents the heavy “nu” chain (Fl-HC), and a
22-kDa molecular size species corresponding to the light chain
(LC) (Figure S1A). A third band was detected with an estimated
molecular size of 40-kDa (Figure S1A), which corresponds to a
smaller form of the heavy chain of IgY (1-HC), produced by
some galliform and non-galliform birds (Lundqvist et al., 2006; Li
et al., 2012). These bands were also observed in electrophoresed
egg yolk from locally acquired eggs (Figure S1A). Western
blot analysis with polyclonal goat IgG against IgY revealed
the presence of two main immunoreactive bands with similar
molecular sizes as Fl-HC and LC, indicating that the 1-HC is
not recognized by the polyclonal anti-IgY antibody (Figure S1B).
To remove the IgY (1Fc) fraction, full-length IgY was further
purified under acidified (pH 4.0) conditions (Hodek et al., 2013)
to a purity of 98% (Figure S1C). Analysis of the purified fractions
of anti-spore IgY revealed an increase in purity of 92 and
95%, for batches 7245 and 7246, respectively (Figure 1A). Acidic
precipitation of IgY does not affect the activity of the antibody,
as the immunoglobulins present high titer against spores. The
titers of purified fractions of anti-spore IgY (i.e., reciprocal of
antibody dilution) for both IgY fractions were determined by
ELISA. The antibody titers for the unpurified IgY fractions of
batches 7245 and 7246 were estimated in 1:128,000 and 1:256,000,
respectively; after purification of full-length IgY, titers of batches
7245 and 7246 increased to 1:256,000 and 1:512,000, respectively
(Figure 1B). These results indicate that acidic purification of full-
length IgY did not affect anti-spore IgY titers against C. difficile
spores.
Saturation and Level of Binding of
Anti-Spore IgY to C. difficile Spores
Nearly 2–10% of IgY has been reported to be antigen specific
(Kovacs-Nolan and Mine, 2004). Therefore, to gain more
information on the anti-spore IgY we determined the percentage
of IgY specific to C. difficile spores to optimize downstream
therapeutic development. The saturation point of the anti-
spore IgY required to cover the surface of 4 × 107 spores
was determined by pre-incubating C. difficile spores with 0.2
to 1.0 mg/mL of anti-spore IgY from batches 7245 and 7246
followed by SDS-PAGE electrophoresis and immunoblotting
(Figures 1C,D). Figures 1C,D demonstrates that C. difficile
spores become saturated with a concentration of anti-spore IgY
of 0.6 mg/mL from either of both batches (i.e., 7245 and 7246).
To determine the number of molecules bound to the spore
surface, a fix number of C. difficile spores was incubated with
a fixed amount of IgY of batches 7245 and 7246. After washes
to remove non-adhered antibodies, proteins from the spores
and attached antibodies were resolved by SDS-PAGE against
a gradient of IgY, and immunoblotted with anti-IgY antibody.
Results show that 0.41 and 0.34 µg of IgY from batches 7245
and 7246, respectively, were estimated to bind to 4 × 107 spores
by densitometry (Figures 1E,F). This corresponds to ∼1% of
total IgY (example of calculation for batch 7246: [percentage of
IgY = (0.34 µg/(0.6 µg/µL) × 50 µL) × 100]). The number of
anti-spore IgY molecules per C. difficile spore of batches 7245
and 7246 were estimated to be 87,141 and 73,124, respectively
(example of calculation for batch 7246: [Number of IgY per
spores = (0.34 µg/((70,000 Da/(6,022 × 1023) × 106/(4 × 107])
(numbers are representative of three independent experiments
with essentially similar results); indicating an adequate level of
opsonization of the spore surface with anti-spore IgY. Based on
these results we designed downstream experiments (i.e., effect
on spore adherence, germination and in vivo infection) using
saturation concentration.
Immunoreactivity of Anti-Spore IgY against
C. difficile Vegetative Cells and Spores
Next, we evaluated the specificity of both batches of anti-spore
IgY against C. difficile spore extracts and lysates by Western
blot analysis. Immunoblotting of R20291 spore extracts with
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FIGURE 1 | Characterization of anti-spore IgY specificity against C. difficile spores. (A) SDS-PAGE of the purification of full length IgY (P) from IgY obtained from the
manufacturer (AL). AL, IgY purified in Aves Labs; P, IgY purified. Arrows show band corresponding to heavy chain (HC), light chain (LC) of IgY and HC-1
corresponding to alternative splicing. (B) Titers of purified anti-spore IgY (Pur) and unpurified anti-spore IgY (Un) of batches 7245 and 7246 and their corresponding
preimmunized IgY (Pre) were compared by ELISA. (C,D) Saturation concentration of IgY binding to C. difficile spores. 4 × 107 spores were incubated with different
concentrations of anti-spore IgY of batches 7245 (C) and 7246 (D) and the amount of the heavy chain IgY (HC) bound to the spore surface was determined by
Western blot with anti-IgY HRP (Abcam). Densitometry analysis of the amount of IgY bounded to the spore surface was analyzed with ImageJ and expressed as
relative to saturation levels. (E,F) Quantitation of the IgY level bound to C. difficile spores. 4 × 107 spores were incubated with anti-spore IgY of batches 7245 and
7246 at saturation concentration (1.2mg/ml), rinsed and the amount of IgY bound to the spore surface determined by a calibration curve of IgY, and estimated to be
0.34 µg of IgY per 4 × 107 spores.
anti-spore IgY of batch 7245 yielded a single immunoreactive
band of ∼130-kDa (Figure 2A), which contrasts with previously
reported immunoreactive species detectable by anti-spore
antibodies generated in goat (Barra-Carrasco et al., 2013; Pizarro-
Guajardo et al., 2014). Strikingly, upon immunoblotting of
R20291 cell lysates of two immunoreactive bands of ∼ 50-
and 38-kDa were evidenced (Figure 2A), indicating that this
batch of anti-spore IgY cross-reacts with C. difficile vegetative
cells. However, upon evaluation of anti-spore IgY of batch
7246 against spore extracts of R20291 strain, we evidenced that
two immunoreactive bands of ∼170- and 100-kDa (Figure 2B),
which are consistent with previous findings using goat anti-spore
IgG (Barra-Carrasco et al., 2013; Pizarro-Guajardo et al., 2014).
Immunoblotting of lysates of vegetative cells revealed that anti-
spore IgY of batch 7246 does not immunoreact with epitopes
of vegetative cells (Figure 2B). By contrast, in immunoblotting
R20291 spore extracts and cell lysates with pre-immunized IgY of
batches 7245 and 7246 (Figures 2A,B) no immunoreactive bands
were detectable, suggesting that immunoreactive protein species
detected by the anti-spore IgY are spore-specific antigens.
To expand this analysis, we included spore extracts and
vegetative cells of another epidemically relevant PCR ribotype
078 (i.e., M120) which is an epidemic strain first identified
in livestock and subsequently identified in clinics across
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FIGURE 2 | Immunoreactivity of anti-spore IgY against C. difficile spores and vegetative cells. (A,B) Immunoblotting of spore extracts and vegetative cell lysate (4 ×
107 spores or vegetative cells) of various C. difficile strains with 1:5000 of preimmunized IgY or anti-spore IgY of batches 7245 (A) and 7246 (B). Spore extracts and
vegetative cells were separated by 12% SDS-PAGE gel, transferred to nitrocellulose membrane an analyzed by Western blot with IgY prior to immunization
(pre-immunized) and anti-spore IgY of batches 7245 (A) and 7246 (B) as described in the Material and Methods section.
Europe (Goorhuis et al., 2008) and a clinically relevant PCR
ribotyope 046 (strain PUC31), isolated from a patient with
recurrent infection. Immunoblotting of spore extracts of
strain M120 and PUC31 with anti-spore IgY of batch 7245
revealed three immunoreactive bands of ∼170-, 37-, and
17-kDa (Figure 2A); however, cross-reactivity with PUC31
cell lysates was evidenced. Upon immunoblotting M120 and
PUC31 spores with anti-spore IgY of batch 7246, ∼170 and
100-kDa and 100- and 37-kDa, respectively (Figure 2B).
This latter batch of IgY did not immunoreact with cell
lysates of both strains (Figure 2B). Collectively, these results
indicate that: (i) anti-spore IgY of batch 7245 not only detects
immunoreactive proteins of spore extracts but also cross-
reacts with proteins of cell lysates and, therefore we reasoned
that this batch is unsuitable for further experimentation;
(ii) anti-spore IgY of batch 7246 uniquely recognizes
spore-specific antigens, and therefore was used for further
experimentation.
Characterization of the Variability of
Binding of Anti-Spore IgY to C. difficile
Spores
To further evaluate the specificity of anti-spore IgY of batch 7246,
we performed an ELISA to test whether anti-spore IgY cross-
reacted against conformational antigens of C. difficile vegetative
cells. As expected, a significant immunoreactivity of anti-spore
IgY was observed against C. difficile spores (Figure 3A); by
contrast, no significant immunoreactivity was evidenced against
vegetative cells, indicating the absence of cross-reactivity of anti-
spore IgY with conformational antigens of vegetative cells.
Recent studies demonstrate that C. difficile forms spores
with two different morphotypes of the outermost exosporium
layer in the same sporulating culture: (i) spores with a thin-
exosporium layer; and (ii) spores with a thick exosporium
layer (Pizarro-Guajardo et al., 2016a,b). These studies have
demonstrated that ∼75% of the spores have a thin exosporium
layer, while 25% of the spores have a thick exosporium layer.
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FIGURE 3 | Characterization of immunoreactivity of anti-spore IgY against C. difficile spores. (A) Immunoreactivity of anti-spore IgY against conformational antigens of
C. difficile spores and vegetative cells was analyzed by ELISA. (B,C) Heterogeneity of binding of anti-spore IgY to C. difficile spores. Representative phase contrast
and anti-spore immunofluorescence micrographs are shown (B). The fluorescence (Fl.) intensity of 300 spores with anti-spore IgY were analyzed and the distribution
of the fluorescence intensity of anti-spore IgY-specific immunofluorescence signal of R20291 spores (C). The median of the fluorescence intensity is shown. The data
shown in (C) is from one experiment that is representative of three independent experiments.
Therefore, we also assessed by indirect immunofluorescence the
heterogeneity of binding of anti-spore IgY to heterogeneous
spore population. Analysis of 300 spores revealed that 100%
of the spores yielded immunofluorescence signal specific for
anti-spore IgY (Figure 3B). Upon quantitative analysis of
the immunofluorescence signal revealed an average relative
fluorescence intensity of 64 arbitrary units for spores incubated
with anti-spore IgY (Figure 3C). Analysis of the distribution
of the fluorescence intensity evidenced that anti-spore IgY
yielded a near normal distribution of the fluorescence intensity
(Figure 3C). Collectively, these observations suggest that, despite
the ultrastructural differences reported in R20291 spores, anti-
spore IgY binds to both morphotypes with a normal distribution.
Opsonization of C. difficile Spores with
Anti-Spore IgY Does Not Affect
Germination
Next, we evaluated whether opsonization of C. difficile spores
would affect their germination ability when incubated at
saturated concentrations of IgY. C. difficile R20291 spores
incubated with anti-spore IgY at concentrations of saturation
caused no significant decrease in the efficiency of spore-colony
formation when plated on BHIS agar plates in presence of sodium
taurocholate (BHIS+ST) (Figure 4A) (ANOVA test followed by
Dunn’s posttest). The effectiveness in inhibition of germination
was also tested in clinical C. difficile isolates; spores from Chilean
isolates PUC31, PUC38, and PUC104 (Plaza-Garrido et al., 2015)
were pre-incubated with anti-spore IgY and plated in BHIS+ST.
No significant decrease in the spore colony forming ability was
observed in IgY-opsonized spores of clinical Chilean strains with
anti-spore IgY (Figure 4B). From these results, we conclude that
opsonization of C. difficile spores with anti-spore IgY does not
affect spore viability.
IgY-Opsonized C. difficile Spores Exhibit
Reduced Adherence to Intestinal Epithelial
Cells
We evaluated if opsonization of C. difficile spores with anti-
spore IgY affects spore adherence to epithelial cells. C. difficile
R20291 spores incubated with saturated and twice saturated
concentration of IgY, presents a significant decrease in spore-
adherence to differentiated Caco-2 cells, estimated in ∼44%
when opsonized with saturation concentration of anti-spore
IgY (Figure 4C). Notably, 2-fold increase in the saturation
concentration of anti-spore IgY lead to an increase in spore
adherence to 68% (Figure 4C), suggesting the formation of
immune complexes that rather than inhibiting, might be favoring
spore adherence. These results, with the optimum concentration
of anti-spore IgY, were further expanded by inclusion of three
C. difficile clinical isolates (i.e., PUC31, PUC38, and PUC104).
Opsonization of spores of these three clinical isolates also
evidenced reduced spore-adherence to intestinal epithelial cells
to a final extent of ∼38 and 73% of total spores when incubated
with saturated amounts of IgY anti-spore, depending on the
isolate (Figure 4D). Collectively, these results indicate that anti-
spore IgY can reduce the adherence of various clinical isolates to
intestinal epithelial cells.
Analysis of the Immunoreactivity of
Anti-Spore IgY against Denatured and
Conformational Antigens of the Murine
Microbiota
An important feature of an orally administered immunotherapy
is that the antibodies should not bind to bacterial cells of the
host microbiota, minimizing it’s impact in the gut microbiome.
Consequently, we evaluated whether the anti-spore IgY of batch
7246 immunoreacted with denaturized antigens of bacterial cells
derived frommice microbiota of healthy mice (non-infectedMb)
and C. difficile infected-mice (infect. Mb). Western blot analysis
with pre-immunized IgY revealed absence of immunoreactive
protein species in extracts of C. difficile spores and bacterial cells
of microbiota from C. difficile infected and non-infected mice
(Figure 5A). Western blot analysis with anti-spore IgY show
no immunoreactivity against proteins present in both bacterial
cell extracts (Figure 5A). To further confirm the absence of
cross-reactivity of anti-spore IgY against murine microbiota’s
bacterial cells, immunoreactivity against conformational antigens
was assessed by ELISA. As expected, a high affinity of anti-spore
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FIGURE 4 | Effect of anti-spore IgY on C. difficile spore-colony formation and adherence to intestinal epithelial cells. (A) Effect of various concentrations of anti-spore
IgY on the efficiency of C. difficile R20291 spores to form colonies as a measure of germination, colony forming units were determined in BHIS agar plates
supplemented with taurocholate (ANOVA test followed by Tukey’s posttest). (B) Effect of anti-spore IgY on the germination efficiency of several C. difficile clinical
isolates. Untreated (blue bars) and anti-spore IgY (0.6 mg/mL)-treated spores (red bars) were plated on BHIS agar plates supplemented with taurocholate and colony
forming units counted (Paired t-test, n.s., no significance). (C) Effect of various concentrations of anti-spore IgY on spore-adherence of C. difficile R20291 spores to
differentiated Caco-2 cells (Student t-test, *P = 0.001; **P = 0.0001). (D) Effect of anti-spore IgY on the adherence of spores of various clinical isolates of C. difficile to
differentiated Caco-2 cells (Paired t-test, n.s, P > 0.05). Blue bars, untreated spores; red bars, anti-spore IgY-treated spores. Data represents the mean of three
independent experiments and error bars are standard error of the mean.
IgY was observed against C. difficile spore extracts, while a lower
affinity of anti-spore IgY was evidenced against bacterial cells of
the murine microbiota (Figure 5B). Based on these results we
speculated that oral administration of anti-spore IgY should be
specific against C. difficile spores with a minimal impact against
murine gut microbiota.
Oral Administration of 600 µg of Anti-Spore
IgY Prior to C. difficile Spore Infection
Prevents Disease Initiation and Reduced
C. difficile Spores in Colonic Tissue
Based on previous studies that administered IgY doses range
from 50 to 100 µg (Liou et al., 2010; Nguyen et al., 2010),
we first evaluated the effect of 100 and 200 µg of IgY per
dose as prophylactic treatment. However, no difference in body
weight, time to diarrhea development, score of diarrhea, spore
shed through feces, cecum toxin titer was evidenced between
untreated and IgY-treated mice (Figure S2). Depending on the
infectious dose, the infection with C. difficile R20291 spores has
been described to be associated with low mortality (Winston
et al., 2016) and also to cause mild clinical manifestations that
lead to self-recovery of the animals (Zackular et al., 2016).
Differences between studies may also be explained by the fact
that gut microbiota has a high inter-laboratory variation as has
been recently evidenced (Lagkouvardos et al., 2016). In this work,
we observed that all of the mice develop mild-diarrhea and we
did not observe moribund animals before the endpoint of the
experiments.
Since administration of 200 µg of anti-spore IgY did not
delay the initiation of CDI, we evaluated whether a 3-fold
increase in the dose of orally administered anti-spore IgY could
delay the initiation of CDI. Antibiotic-treated C57BL/6 mice
were challenged with 6 × 107 spores (n = 12 per treatment),
clinical symptoms were monitored daily, and fecal samples,
cecum content and colonic tissue were collected (Figure 6A).
A slight but not significant difference in body weight loss was
observed between untreated- and anti-spore IgY-treated mice
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FIGURE 5 | Immunoreactivity of anti-spore IgY against murine microbiota. (A) Western blot analysis of immunoreactivity of IgY against microbiota lysates. Bacterial
cells from fecal microbiota (Mb), C. difficile infected-mice (Positive micro), and microbiota mixed with R20291 spores (108/ml) were electrophoresed, transferred to a
nitrocellulose membrane and probed with pre-immunized and anti-spore IgY. C. difficile R20291 spores were used as a positive control. No immunoreactive band was
observed in Positive micro, presumably due to low relative abundance of C. difficile spores in bacterial cell lysates. (B) Immunoreactivity of anti-spore IgY against
conformational antigens of bacterial cells of the fecal microbiota of mice was detected by ELISA. As a positive control, C. difficile R20291 spores were used.
during the first 3 days after infection (Figure 6B). Notably,
administration of anti-spore IgY caused a significant delay of 2
days in the appearance of diarrheic symptoms (Log-rank test,
P ≤ 0.01) (Figure 6C); the median time to diarrhea was 1.5 days
for untreated mice and 3.5 days for anti-spore IgY-treated mice
(Figure 7C). The score of diarrhea was also lower (Student t-
test, P= 0.0429) in anti-spore IgY-treated mice than in untreated
mice (Figure 6D). Despite a slight decrease in the overall
histopathological score (Mann-Whitney unpaired, P = 0.45), no
significant difference was observed between untreated (3.83 ±
0.7) and anti-spore IgY-treated mice (3.0 ± 0.4) (Figure 6E and
Figure S3). No significant difference was evidenced in the levels
of spores shedded in feces between untreated and anti-spore
IgY-treated mice at 0, 1, 2, 3, and 4-day post-infection (Mann-
Whitney unpaired test, day 0 P= 0.86; day 1 P= 0.062; day 2 P=
0.19; day 3 P= 0.41; day 4 P= 0.86) (Figure 6F). Administration
of anti-spore IgY had no effect on cytotoxic titers of cecum
contents, with no significant difference (P = 0.65) observed
between untreated and anti-spore IgY treated mice (Figure 6G).
Strikingly, administration of anti-spore IgY caused a significant
reduction (P = 0.03) of ∼90% of C. difficile R20291 spores in
colonic tissue vs. untreated mice (Figure 6H). Collectively, these
observations indicate that administration of anti-spore IgY prior
and during infection, delays the initiation of CDI and reduces the
spore-load in colonic tissue.
Effect of Oral Co-administration of 600 µG
of Anti-Spore IgY with Vancomycin during
a Recurrence Model of CDI
Given the ability of anti-spore IgY to reduce adhered spores to
colonic tissue, we sought to evaluate whether administration of
anti-spore IgY in combination with vancomycin would delay
the development of recurrence. Consequently, we used a mouse
model of recurrence, where infection recurrence can be induced
after a 7-day regime of orally administered vancomycin 3 days
post-infection. A group of C. difficile-challenged mice (n= 12)
were treated with vancomycin (control for recurrence) and
another group of C. difficile-challenged mice (n = 12) were
treated with vancomycin and anti-spore IgY (Vancomycin/IgY)
(Figure 7A). No difference in the time to the first episode of
diarrhea (Log-rank, P = 0.45) (Figure 7B) and overall score of
diarrhea (Mann-Whitney unpaired, P = 0.88) (Figure 7C) were
observed post-C. difficile-challenge between both groups of mice.
However, after administration of a 7-day regime of vancomycin,
100% of vancomycin treated mice exhibited diarrhea after 1 day-
post vancomycin treatment (Figure 7D). By contrast, only 30% of
Vancomycin/IgY-treated mice exhibited diarrhea after 1-day post
Vancomycin/IgY-treatment (Figure 7D). The co-administration
of Vancomycin/IgY caused a delay in the occurrence of diarrhea
by a median of 1.5 days (P = 0.0021) (Mann Whitney unpaired
t-test; P = 0.104) (Figure 7D). Histological score of mice
treated with Vancomycin/IgY (3.3 ± 0.6) was slightly lower
(Unpaired t-test with Welch’s correction; P = 0.08) compared
to mice treated with vancomycin alone (5.0 ± 0.6) (Figure 7F
and Figure S3), which could be attributed to the lower tissue
damage and prevention of the recurrence of the disease. Based
on these observations, we suggest that co-administration of
Vancomycin/IgY reduces the recurrence of diarrhea.
C. difficile spore-load in feces, cecum content cytotoxicity and
spores adhered to colonic tissue were also evaluated. Wilcoxon
matched-pairs signed rank test revealed significant differences (P
= 0.002) in C. difficile spores shed in feces between vancomycin-
and Vancomycin/IgY-treated mice (Figure 7G). A significant
increase in C. difficile spores in feces was observed at day 4
and 5 after infection; at day 4, mice treated with vancomycin
and Vancomycin/IgY released 3.63 and 3.93, respectively
(Mann-Whitney unpaired test, P ≤ 0.05), while at day 5, fecal
shedding for vancomycin and Vancomycin/IgY-treated mice
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FIGURE 6 | Administration of 600 µ g of anti-spore IgY during the initiation of CDI. (A) Overview of the experimental design schematics for the prevention of initiation
of C. difficile infection in a murine model. Antibiotic treated C57BL/6 mice were infected with C. difficile R20291 spores (6 × 107 spores; n = 12 per group) and
subsequently treated with oral administration of anti-spore IgY or phosphate buffer saline as a control for 3 days. (B) Body weight change was slightly higher in
untreated mice (blue line) and mice treated with anti-spore IgY (red line). Untreated and anti-spore IgY-treated C. difficile-challenged mice were monitored for: (C) time
to diarrhea; (D) score of diarrhea; (E) Colonic histological scores; (F) Fecal C. difficile spore shedding; (G) Cecum content cytotoxicity; (H) C. difficile spores in colonic
tissue. Data of Figure 7 is representative of two independent experiments. Error bars are standard error of the mean. n.s., is no significance; *P ≤ 0.05.
was of 3.21 and 3.63 Log CFU, respectively (Mann-Whitney
unpaired test, P ≤ 0.05). Notably, at the end of treatment (i.e.,
day 10), vancomycin and Vancomycin/IgY-treated mice had fecal
shedding levels of 3.22 and 3.14 Log CFU, respectively (Mann-
Whitney unpaired test, P ≤ 0.05), suggesting that administration
of anti-spore IgY contributed to the increased fecal spore-
shedding, presumably due to a dual effect of vancomycin
targeting vegetative cells and anti-spore IgY targeting C. difficile
spores. No significant difference in cecum content cytotoxicity
between vancomycin (6.6 ± 0.3) and Vancomycin/IgY-treated
(6.4 ± 0.2) mice 5 days after treatment was evidenced (Mann-
Whitney unpaired test, P = 0.62) (Figure 7H). Similarly, no
significant difference in the number of spores adhered to
colonic tissue (Mann-Whitney unpaired test, P = 0.69) between
both groups of mice treated with vancomycin (5.5 ± 0.23)
and Vancomycin/IgY (5.7 ± 0.22) was evidenced (Figure 7I).
Collectively, these results suggest that rapid outgrowth of C.
difficile occurs after Vancomycin/IgY treatment, leading to
recolonization and toxin production in the cecum.
No IGG Response to IgY and C. difficile
Spores Was Observed in the Mice during
the Course of CDI in Initiation and
Recurrence Model
We also analyzed whether IgG against the administered IgY
as treatment were raised. Serum from C. difficile-challenged
mice treated with anti-spore IgY (initiation group) and
Vancomycin/IgY (recurrence group) and untreated mice (naive).
No immunoreactivity against IgY was evidenced between all
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FIGURE 7 | Oral administration of anti-spore IgY in combination with vancomycin delays the occurrence of recurrent CDI in a murine model. (A) Overview of the
experimental design schematics for the prevention of the recurrence of C. difficile infection in a murine model. Antibiotic treated C57BL/6 mice were infected with C.
difficile R20291 spores (6 × 107 spores; n = 10 per group) and subsequently orally treated with anti-spore IgY and vancomycin or with vancomycin alone for 7 days.
C. difficile-challenged mice treated with vancomycin or Vancomycin/IgY were monitored for: (B) time to diarrhea during first episode; (C) score of diarrhea during first
episode; (D) time to diarrhea during recurrence of CDI; (E) diarrhea score during recurrence of CDI; (F) Colonic histological scores during recurrence of CDI; (G) Fecal
C. difficile spore shedding; (H) Cecum content cytotoxicity; (I) C. difficile spores in colonic tissue. Data of Figure 7 is representative of two independent experiments.
Error bars are standard error of the mean. n.s., is no significance; *P ≤ 0.05.
three groups of mice (Kruskal-Wallis ANOVA, P = 0.602)
(Figure S4A). No significant difference in serum reactivity
against C. difficile R20291 spores between these groups of mice
(i.e., naive, Initiation and recurrence) (Kruskal-Wallis ANOVA,
P= 0.082) (Figure S4B) was observed. These results demonstrate
that during the treatment to prevent initiation and recurrence
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models of the infection, no significant immune response was
generated against IgY administered as treatment or C. difficile
spores during the treatment of the initiation and recurrence
models of the infection.
DISCUSSION
Passive immunization is the transfer of active humoral immunity
in the form of ready-made antibodies. Some mechanisms of host
protection by oral administration of IgY have been proposed and
include: (i) inhibition of pathogen adhesion to cell surfaces; (ii)
bacterial agglutination and flushed down the gut (Rahman et al.,
2013). Therefore, given that C. difficile spores play an important
role in the initiation and persistence of the infection, the goal of
this study was to evaluate: (i) whether IgY could be specifically
raised against C. difficile spores; and (ii) oral administration of
anti-spore IgY during initiation and recurrence of CDI. In this
context, our results provide several noteworthy observations that
are further discussed.
This work demonstrates that significant differences in
C. difficile spore-specific IgY obtained from two hens. Titers
of batch 7245 were 2-fold lower than batch 7246, which could
be attributed to the differences in the immunoreactive species
detected by each batch (Figure 2). Although the reasons for
these differences are unclear, the fact that IgY of batch 7245, but
not it’s pre-immunized IgY, immunoreacted with vegetative cells
suggests that during immunization, this chicken was exposed
to C. difficile vegetative cells. Due to these uncertainties, IgY
from batch 7245 was discarded from further experiments. It
was also noteworthy that despite the elevated number of protein
species present in the spore surface (i.e., ∼180) (Díaz-González
et al., 2015), only two species of molecular masses of ∼170-
and 100-kDa were found to be immunoreactive against anti-
spore IgY (batch 7246) (Figure 2). Although the nature of
these immunoreactive protein species is unclear, their molecular
masses seems to be strain dependent, suggesting differences
between strains in the assembly of the outermost layers. These
proteins also seem to be abundant in the spore surface of strain
R20291, as evidenced by the elevated number of IgY molecules
that saturate the spore surface (∼70,000 molecules per spore).
Further work oriented to identify these immunoreactive proteins
is underway.
A notable observation of this work is that anti-spore IgY
binds to the entire spore population. Recently, several studies
have highlighted that during sporulation, C. difficile forms spores
with two different exosporium morphotypes: (i) spores with
an exosporium layer which is thin in the amount of electron-
dense material that surrounds the spore coat; and (ii) spores
with an exosporium layer thick in electron-dense material
surrounding the spore coat (Pizarro-Guajardo et al., 2016a,b).
The relative abundance of each exosporium morphotype is
strain-dependent; in the case of strain R20291, spores with a
thin- and thick-exosporiummorphotype represent∼75 and 25%
of the spore population, respectively (Pizarro-Guajardo et al.,
2016a,b). In R20291 spores, both types of spore have hair-like
extensions, which is a typical feature of epidemically relevant
strains (Pizarro-Guajardo et al., 2016a). In this context, and
despite these ultrastructural differences, quantitative analysis of
the immunofluorescence intensity reveals a normal distribution,
indicating that the immunoreactive protein specie or species
are present in the entire spore population and therefore, their
presence is likely not affected by the ultrastructural variability
observed in the exosporium layer of C. difficile spores.
A main conclusion of this work is that anti-spore IgY reduces
spore adherence to intestinal epithelial cells. The mechanism(s)
of adherence of C. difficile spores to intestinal epithelial cells
remains elusive; several reports suggest that spore ligand(s)
and cellular receptor(s) are involved but have failed to identify
such molecules (Paredes-Sabja and Sarker, 2012; Mora-Uribe
et al., 2016). Notably, despite the saturation of C. difficile spore
surface with an elevated number of anti-spore IgY molecules,
spore-adherence to intestinal cells only decreased by ∼50%,
suggesting that opsonization of the spore surface with anti-spore
IgY does not completely block spore-ligand(s) involved in spore-
adherence to intestinal cells. This suggests that anti-spore IgY
immunoreacts with spore-surface epitopes that are not involved
in spore adherence and that are present in various clinically
relevant C. difficile strains. A previous report suggested that
the hair-like extensions of the spore surface might be involved
in spore-adherence (Mora-Uribe et al., 2016); therefore, IgY
antibodies against these structures might inhibit spore-adherence
more efficiently. Further experimentation aiming to determine
whether these hair-like extensions are made of the collagen-like
BclA2 and/or BclA3 by using transmission electron microscopy
and immunogold antibodies will provide conclusive evidence
of their composition and aid in the development of IgY-based
therapies.
The approach of using specific IgY for prevention
and treatment of CDI offers an alternative to current
immunotherapies, which use intravenous administration of
anti-TcdA and TcdB monoclonal human antibodies (Negm
et al., 2017). To the best of our knowledge, there are no reported
prophylactic therapies that target to prevent the initiation
of CDI in a susceptible host by removing C. difficile spores
from the host. In this context, here, we provide evidence that
a spore-oriented therapy using chicken IgY, from C. difficile
spore-immunized hens, administered in a prophylactic manner
prior and during the infection can delay the initiation of CDI.
The effect of oral administration of 600 µg per dose of anti-spore
IgY as prophylactic therapy contributed mainly to delay the
initiation of diarrhea and to reduce the spore load in colonic
tissue. Initial doses of 100 and 200 µg of IgY, administered in
50 µl at 2 and 4 mg/ml which were ∼3 and 6-fold higher than
the in vitro saturation concentration, were ineffective. This could
be attributed to: (i) in vivo dilution of IgY below an effective
concentration to efficiently opsonize the spore; and/or (ii) to
proteolytic degradation of IgY by digestive enzymes. Despite the
drawbacks in the administration format used in this work, we
observed that increasing the dose to 600 µg (i.e., 12 mg/ml) was
sufficient to cause a delay in the initiation of diarrhea. It was
notable to observe that administration of IgY had no impact in
fecal shedding of C. difficile spores, which could be attributed
by anti-spore IgY being unable to recognize sporulating cells. A
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 13 August 2017 | Volume 7 | Article 365
Pizarro-Guajardo et al. C. difficile Spore Passive Immunotherapy
major drawback of oral administration of anti-spore IgY was the
negligible decrease in cecum content cytotoxicity. The data also
demonstrates that administration of anti-spore IgY reduces the
spore load in the colonic tissue; however, this might not be the
case for C. difficile spores in cecum contents, were no reduction
in cytotoxicity was detectable during IgY treatment. The latter
suggests that opsonized spores able to germinate and release the
nascent cell are capable of colonizing the cecum and establishing
the infection. Our in vitro results demonstrate that opsonization
of C. difficile spores with anti-spore IgY has no effect on
spore colony forming efficiency and support this notion.
In the GI tract of antibiotic-treated mice, C. difficile spores
encounter favorable conditions of bile acids that trigger spore
germination and outgrowth (Buffie et al., 2015). To overcome
this limitation, oral administration of anti-spore IgY could be
combined with taurocholate analogs shown to inhibit spore
germination and progression of the disease in mouse models
(Sorg and Sonenshein, 2009; Howerton et al., 2013). In summary,
further optimization of IgY based oral immunotherapy could
include a mixture of IgY specific against spores, vegetative
cells and toxins, and bile acid analogs inhibitors of spore
germination.
A major clinical challenge in CDI treatment is the elevated
rate of recurrence of the infection (Evans and Safdar, 2015).
C. difficile sporulation during infection is essential for the
recurrence of the disease (Deakin et al., 2012); current antibiotic-
therapies (i.e., metronidazole and vancomycin) to treat C. difficile
infections have effect on the spores being produced during the
infection which can persist and cause infection recurrence. In
this context, we demonstrate that administration of anti-spore
IgY in combination with vancomycin during CDI treatment
delays the appearance of diarrhea. Notably the impact of this
combined therapy on the histopathological score was modest
presumably because most of the histological damage occurred
during the first episode of the infection and also due to the
lack of differences in cecum content cytotoxicity. The timing
of the measurements (day 5 after IgY-vancomycin treatment)
could have affected our results, allowing C. difficile to re-
colonize, release toxins and sporulate leading to negligible
differences in the latter phenotypes. Unfortunately, in this work
we did not evaluate the dynamics of removal of C. difficile
spores from colonic tissue during IgY-vancomycin nor the
composition/structure of the microbiota, which could have
provided a deeper insight on the effects of oral administration of
specific IgY.
In summary, in this work we demonstrate that highly specific
chicken IgY antibodies can be raised against C. difficile spores,
with minimal cross-reactivity with bacterial cells of the murine
microbiota. Notably, we provide experimental evidence that
suggest that the administration of anti-spore IgY can be used
for two different purposes (i) as a prophylactic therapy when
administered orally in susceptible patients prior to the initiation
of the infection, to delay the initiation of C. difficile-associated
diarrhea; (ii) in combination with vancomycin, to delay the
appearance of recurrent diarrhea. Although the IgY based
treatments shown in this work can be clearly optimized, we
believe that this study provides a starting platform for further
development of alternative passive immunotherapies to combat
CDI and help reduce the incidence of CDI and of recurrent CDI.
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Figure S1 | Presence of an alternative splicing variant of the heavy chain and
scheme of the purification protocol of full-length IgY through salting out under
acidic conditions. (A,B) SDS-PAGE (A) and western blot (B) analysis of the IgY
suspensions obtained from AvesLab. Total proteins of egg yolk (control) and
AvesLab IgY suspension of batches 7245 and 7246 were electrophoresed and
stained with Coomassie G250. Arrows indicate the position of the full length heavy
chain (Fl-HC), the alternative splicing variant of the heavy chain (1-HC), and light
chain of IgY (LC) of molecular mass of ∼75-80-, 38-, and 23-kDa, respectively. (C)
Purification protocol of fill-length IgY. IgY suspension (1) is diluted 1:20 with saline
solution (2), followed by pH adjustment to 4.0 (3) and centrifugation at 3,700 g for
20 min at 4◦C (4). Next, the pellet, containing precipitated full-length IgY, is
resuspended in 1 ml of PBS (5) filter-sterilized, and aliquots stored at −20◦C until
use (adapted from: (Hodek et al., 2013)).
Figure S2 | Administration of 100 and 200 µg of anti-spore IgY during the initiation
of CDI. (A) Overview of the experimental design schematics for the prevention of
initiation of C. difficile infection in a murine model. Antibiotic treated C57BL6 mice
were infected with C. difficile R20291 spores (6 × 107 spores; n = 3 per group)
and subsequently treated with oral administration of anti-spore IgY or phosphate
buffer saline as a control for 3 days. (B) Body weight change of untreated mice
(blue line) and mice treated with 100 µg (red line) and 200 µg (green line) of
anti-spore IgY and with 200 µg of pre-immunized IgY (gray line).
C. difficile-challenged mice were monitored for: (C) time to diarrhea; (D) score of
diarrhea; (E) Fecal C. difficile spore shedding; (F) Cecum content cytotoxicity at
sacrifice; Data are representative of two independent experiments. Error bars are
standard error of the mean. n.s., no significance; ∗P ≤ 0.05; ∗∗P ≤ 0.01. (D,F)
Un, untreated; 100, is 100 µg of anti-spore IgY; 200, is 200 µg of anti-spore; Pre
200, is 200 µg of pre-immunized anti-spore IgY.
Figure S3 | Histological examination of colonic tissues obtained from antibiotic
treated mice exposed to C. difficile. Micrographs show colonic tissue of: (A)
Non-infected mouse colon; (B) Colon from mice infected with C. difficile (control in
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initiation model); (C) Colon from mouse treated with IgY anti-spore prior and after
infection (initiation model); (D) Colon from mouse infected and treated with
vancomycin (recurrence model); (E) Colon from mouse infected and treated with
vancomycin combined with IgY anti-spore. Black arrow shows edema, and arrow
head shows neutrophilic recruitment.
Figure S4 | Serum titers raised against IgY and C. difficile spores during initiation
and recurrence of CDI. Serum of naive mice, as a control, mice of the infection
experiment (infection), and mice of the recurrent infection experiment (recurrence)
were isolated and reactivity against C. difficile spores (A) and anti-spore IgY (B)
was analyzed by ELISA as described in Methods.
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